Buy-rated reports

573 tickers rated Buy
Ranks this page's recent reports by score.
Invitation Homes Inc.
INVH·Real Estate
A ★★★★Buy
Current$26.56
Target$29.24
Return+10.1%
Oct 31, 2026

Invitation Homes offers recurring single-family rental income, an attractive dividend, and potential valuation recovery through disciplined capital recycling, although slowing rent growth and property cost inflation threaten AFFO expansion.

Score
78
Essex Property Trust, Inc.
ESS·Real Estate
A ★★★★Buy
Current$264.18
Target$283.05
Return+7.1%
Oct 31, 2026

Essex offers durable West Coast apartment income, resilient occupancy, and steady dividends with potential rental growth upside, although geographic concentration, financing costs, and a limited valuation discount constrain returns.

Score
75
VICI Properties Inc.
VICI·Real Estate
A ★★★★Buy
Current$24.46
Target$28.00
Return+14.5%
Oct 31, 2026

VICI Properties offers durable contractual rental income, a high dividend yield, and an attractive AFFO valuation, but concentrated casino tenant exposure and rising credit-loss allowances threaten the reliability of its future cash flows.

Score
79
Universal Health Services, Inc.
UHS·Healthcare
A ★★★★Buy
Current$176.05
Target$208.17
Return+18.2%
Oct 31, 2026

Universal Health Services offers substantial cash generation and a historically discounted valuation supported by durable hospital demand, although Medicaid reimbursement pressure and weakening acute-care margins threaten earnings recovery.

Score
77
Graco Inc.
GGG·Industrials
A ★★★★Buy
Current$67.44
Target$78.20
Return+16.0%
Oct 31, 2026

Graco combines a durable industrial-equipment moat, strong cash generation and historically compressed valuation multiples, although cyclical demand, margin pressure and acquisition integration could delay earnings recovery.

Score
84
Globe Life Inc.
GL·Financials
A ★★★★Buy
Current$159.08
Target$182.60
Return+14.8%
Oct 31, 2026

Globe Life offers recurring insurance earnings, attractive operating ROE, and accretive buybacks at a modest valuation, although health underwriting volatility, agency productivity weakness, and unresolved litigation could constrain returns.

Score
75
Verizon Communications Inc.
VZ·Communication Services
A ★★★★Buy
Current$44.73
Target$49.88
Return+11.5%
Oct 31, 2026

Verizon offers attractive dividend income and improving wireless and fiber cash generation at a modest forward valuation, although heavy debt and competitive network spending constrain upside and financial flexibility.

Score
78
Tenet Healthcare Corporation
THC·Healthcare
A ★★★★Buy
Current$273.25
Target$300.00
Return+9.8%
Oct 31, 2026

Tenet combines improving hospital margins, a high-return ambulatory surgery network, and strong cash generation, offering attractive compounding potential despite reimbursement pressure, labor inflation, and meaningful financial leverage.

Score
82
Otis Worldwide Corporation
OTIS·Industrials
A ★★★★Buy
Current$75.75
Target$87.00
Return+14.9%
Oct 31, 2026

Otis offers a durable, high-return elevator service franchise at a historically compressed valuation, with modernization growth supporting earnings recovery despite persistent margin pressure, China construction weakness, and leverage.

Score
82
Edwards Lifesciences Corporation
EW·Healthcare
A ★★★★Buy
Current$92.01
Target$97.15
Return+5.6%
Oct 31, 2026

Edwards Lifesciences combines a durable, high-margin TAVR franchise with expanding mitral and tricuspid treatment opportunities, although premium valuation and competitive risks limit its margin of safety.

Score
84
CME Group Inc.
CME·Financials
A ★★★★Buy
Current$303.14
Target$319.92
Return+5.6%
Oct 31, 2026

CME combines deeply entrenched derivatives-market liquidity with exceptional cash generation and attractive shareholder distributions, although premium valuation and emerging competition limit its margin of safety.

Score
84
Teledyne Technologies Incorporated
TDY·Technology
A ★★★★Buy
Current$658.23
Target$742.50
Return+12.8%
Oct 31, 2026

Teledyne combines durable imaging and defense-electronics franchises with strong cash generation and growing demand, but premium valuation and acquisition integration risks limit its margin of safety.

Score
82